BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.48
+0.18 (+2.86%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.30
Open6.59
Bid0.00 x 1100
Ask0.00 x 900
Day's Range6.35 - 7.21
52 Week Range3.50 - 1,332.00
Volume837,720
Avg. Volume397,815
Market Cap14.734M
Beta0.33
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.50
Trade prices are not sourced from all markets
  • Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record
    PR Newswire18 hours ago

    Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record

    SAN DIEGO, July 19, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today issued a reminder to shareholders that the record date of its proposed rights offering is Monday, July 23, 2018. To be a shareholder of record on the record date, ownership of Biocept stock must occur by market close on Thursday, July 19, 2018 to account for settlement.

  • Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session
    Zacks4 days ago

    Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session

    Biocept (BIOC) was a big mover last session, as the company saw its shares rise more than 9% on Friday amid huge volumes.

  • ACCESSWIRE4 days ago

    Today's Research Reports on Stocks to Watch: Biocept and Johnson and Johnson

    NEW YORK, NY / ACCESSWIRE / July 16, 2018 / Johnson & Johnson shares saw a drop on Friday as traders reacted to last week’s court decision that the company owes $4.69 billion to 22 women over its talc-based products allegedly causing them cancer. The company is vehement on appealing the court order. Biocept shares were skyrocketing on an announcement that it has entered into an agreement with Alliance Global FZ to market and distribute liquid biopsy testing in the Middle East, Southeast Asia, and the Africa region.

  • Why RH, Biocept, and Lowe's Jumped Today
    Motley Fool6 days ago

    Why RH, Biocept, and Lowe's Jumped Today

    One of these companies said investors shouldn't worry about proposed China tariffs.

  • Why Biocept’s Stock Price Is Soaring Today
    Market Realist6 days ago

    Why Biocept’s Stock Price Is Soaring Today

    Today, Biocept (BIOC) is trading at a stock price of $10.72, which represents ~63.66% growth from yesterday’s close of $6.55.

  • InvestorPlace6 days ago

    BIOC: What’s Going on With Biocept Stock?

    Biocept stock (NASDAQ:BIOC) was skyrocketing on Friday as the company announced a biopsy testing partnership with Alliance Global FZ. Biocept’s bread and butter is the development and administration of liquid biopsy tests that allow physicians to amass clinically actionable information to help improve the outcomes of patients who have been diagnosed with cancer. The company has inked a deal with Alliance Global to market and distribute Biocept’s Target Selector liquid biopsy tests.

  • Why Biocept, Inc. Is Rebounding Big-Time Today
    Motley Fool7 days ago

    Why Biocept, Inc. Is Rebounding Big-Time Today

    The molecular diagnostics company inked a new distribution deal that helped investors forget yesterday's bad news.

  • Benzinga7 days ago

    Biocept Rallies On Marketing Agreement For Proprietary Liquid Biopsy Tests

    Biocept Inc (NASDAQ: BIOC ) shares were ripping higher Friday following the announcement of a provider agreement with Alliance Global. The stock was rallying 58.32 percent to $10.31 at the time of publication.  ...

  • Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region
    PR Newswire7 days ago

    Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region

    SAN DIEGO, July 13, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept's Target Selector™ liquid biopsy tests in the United Arab Emirates and select countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia (MEAA) region. All diagnostic testing services under this agreement will be performed in Biocept's San Diego-based CLIA-certified laboratory with Alliance Global having responsibility for sales, marketing, distribution, and reimbursement of the Company's liquid biopsy platform.

  • Why Biocept, Inc. Stock Is Plunging Today
    Motley Fool8 days ago

    Why Biocept, Inc. Stock Is Plunging Today

    Shares of the small molecular diagnostics specialist took a beating after it announced an infrequently used method to raise cash.

  • ACCESSWIRE8 days ago

    Today's Research Reports on Trending Tickers: Biocept and Myriad Genetics

    NEW YORK, NY / ACCESSWIRE / July 12, 2018 / U.S. equities saw losses on Wednesday, breaking a winning streak of four consecutive days, as trade tensions grew following the White House's announcement of ...

  • Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering
    PR Newswire9 days ago

    Biocept Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

    SAN DIEGO , July 11, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable ...

  • PR Newswire25 days ago

    Biocept Highlights Recent Progress and Outlines Near-Term Strategic Priorities in CEO Letter to Stockholders

    In the past several months we have undertaken a range of initiatives that capitalize on our proprietary technology platform and support our portfolio of commercial tests that provide clinically actionable information from a simple blood sample.

  • ACCESSWIRElast month

    Free Stock Performance Review on Agilent Technologies and Three Additional Medical Research Stocks

    Today, WallStEquities.com evaluates the following Medical Laboratories and Research stocks: Agilent Technologies Inc. (NYSE: A), Biocept Inc. (NASDAQ: BIOC), Co-Diagnostics Inc. (NASDAQ: CODX), and HTG Molecular Diagnostics Inc. (NASDAQ: HTGM). Companies in the medical laboratories market are independent, commercial enterprises that provide information to healthcare professionals about the severity, onset, and reason of patients' physical ailments.

  • Published Case Report Demonstrates the Clinical Utility of Biocept's CTC Platform in the Management of Patients with Metastatic Breast Cancer
    PR Newswirelast month

    Published Case Report Demonstrates the Clinical Utility of Biocept's CTC Platform in the Management of Patients with Metastatic Breast Cancer

    SAN DIEGO, June 18, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed case report demonstrating the clinical utility of its Target Selector™ circulating tumor cell (CTC) testing in the management of a patient with metastatic breast cancer. Biocept's CTC-based assay detected estrogen receptor (ER) expression and HER2 gene amplification, which enabled the patient to qualify for anti-HER2 therapy that extended her survival and improved her quality of life.

  • VWR, Part of Avantor, and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs
    PR Newswirelast month

    VWR, Part of Avantor, and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs

    Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature ...

  • Biocept to Present at the 8th Annual LD Micro Invitational Conference on June 5
    PR Newswire2 months ago

    Biocept to Present at the 8th Annual LD Micro Invitational Conference on June 5

    SAN DIEGO , May 29, 2018 /PRNewswire/ --  Biocept, Inc.  (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...

  • ACCESSWIRE2 months ago

    Agilent Technologies and Three More Healthcare Stocks Under Our Scanner

    This Thursday, WallStEquities.com has initiated reports coverage on the following Healthcare equities: ConforMIS Inc. (NASDAQ: CFMS), DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Agilent Technologies Inc. (NYSE: A), and Biocept Inc. (NASDAQ: BIOC). Billerica, Massachusetts headquartered ConforMIS Inc.'s stock finished Wednesday's session 2.19% lower at $1.34 with a total trading volume of 380,145 shares.

  • Biocept Reports First Quarter 2018 Financial Results
    PR Newswire2 months ago

    Biocept Reports First Quarter 2018 Financial Results

    Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , May 15, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to ...

  • Biocept to Release First Quarter 2018 Financial Results and Host Investor Conference Call on May 15, 2018
    PR Newswire2 months ago

    Biocept to Release First Quarter 2018 Financial Results and Host Investor Conference Call on May 15, 2018

    SAN DIEGO , May 8, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable  ...

  • Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer
    PR Newswire3 months ago

    Case Report in Journal of Thoracic Oncology Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for Patient Diagnosed with Non-Small Cell Lung Cancer

    SAN DIEGO, May 1, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a "letter to the editor" in a prominent lung cancer journal highlighting the clinical utility of its Target Selector™ ROS1 gene rearrangement test. Biocept's circulating tumor cell (CTC)-based assay confirmed detection of a ROS1 gene translocation in a patient diagnosed with non-small cell lung cancer who had previously received chemotherapy and was progressing.

  • Published Case Study Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for ALK Rearrangements
    PR Newswire3 months ago

    Published Case Study Demonstrates the Clinical Utility of Biocept's Liquid Biopsy Test for ALK Rearrangements

    SAN DIEGO, April 27, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a case report demonstrating the clinical utility of its Target Selector™ ALK gene rearrangement test. The circulating tumor cell (CTC)-based assay detected the ALK gene translocation in a patient diagnosed with non-small cell lung cancer who subsequently received sequential ALK inhibitor therapies and exhibited excellent clinical response to treatment.

  • Biocept to Webcast Presentation at the 7th Annual MicroCap Conference
    PR Newswire3 months ago

    Biocept to Webcast Presentation at the 7th Annual MicroCap Conference

    A live webcast of the corporate presentation will be available on the Company's website at ir.biocept.com. Mr. Nall will also cohost the Cancer Research Roundtable, being held April 9 at 9:30 a.m. Eastern time. The roundtable will feature CEOs from leading companies in the cancer research field discussing innovative solutions for patients with cancer.

  • ACCESSWIRE3 months ago

    Free Post Earnings Research Report: Exact Sciences’ Quarterly Revenues Jumped 148.02%

    Stock Monitor: Biocept Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS ) ("EXAS"). ...

  • Biocept to Present at the 7th Annual MicroCap Conference
    PR Newswire4 months ago

    Biocept to Present at the 7th Annual MicroCap Conference

    Company to also co-host roundtable discussion SAN DIEGO , April 3, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians ...